Adverse Events Reporting
The ASRS Research and Safety in Therapeutics (ReST) Committee is dedicated to keeping you apprised of adverse events (AEs) associated with all retina drugs and devices. Our peer-to-peer reporting system serves as a post-market data and safety monitor to help protect patients.
The committee works closely with the US Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) to identify and investigate AEs.
The ReST Committee has investigated numerous AEs and has alerted ASRS members about events ranging from cases of ocular inflammation/noninfectious endophthalmitis following intravitreal injections to cases of suspected fungal endophthalmitis following adjuvant-assisted vitrectomy procedures.
Report AEs to the ReST Committee
If any of your patients experience an adverse event, report it to the ReST Committee as soon as possible. A ReST Committee member will follow up with you to gather detailed information about the AE, work with industry where appropriate, and assess whether the situation warrants an alert to ASRS members.
In addition, please report all adverse events to the manufacturer and FDA Medwatch.
ReST News
The ReST Committee generates member alerts, conducts literature reviews and drafts white papers and articles to provide members with timely information about emerging events on developments and events that may impact patient safety.
- FDA: Avastin, Other Compounded Products Voluntarily Recalled by Ranier's Rx Laboratory Jul 30, 2018
-
Member Alert: 43 Adverse Events Reported After Eye Injections
of Triamcinolone-Moxifloxacin Compounded by Dallas Pharmacy June 15, 2018 - FDA Announces 2 Recalls of Sterile Injectables April 13, 2018
- BD Issues Statement on Incidence of Inflammation Following EYLEA Injections Mar 5, 2018
- Regeneron Releases Statement on Incidence of Inflammation Following Eylea Injections Mar 2, 2018
- Update on Intraocular Inflammation after Eylea Injection Jan 31, 2018
- Member Update: Inflammation after Intravitreal Aflibercept Jan 2, 2018
- Member Alert: PharMEDium Services Recalls Compounded Bupivacaine Jan 2, 2018
- Member Alert: Inflammation after intravitreal aflibercept Oct 13, 2017
- ReST Committee Reviews YAG Vitreolysis of Visually Significant Floaters Feb 22, 2017
-
ASRS Tracking Spike in Reports of Cornea Complications Possibly Linked to Lubricant Use During Vitrectomy Sep 26, 2016
-
Member Alert: Silicone Oil Droplets Aug 16, 2016
- Rare, Serious Condition Can Affect Patients Following Uncomplicated Cataract Surgery—Exploring Possible Link to Vancomycin August 27, 2015
- White paper: A Review of the Frequency and Possible Pathogenesis of Sterile Endophthalmitis Associated With Intravitreal Injections
- Report and talking points: MMWR Notes and CDC Talking Points from the Field: Fungal Endophthalmitis
- Retina Times article: Considerations for chromovitrectomy: Implications of endophthalmitis outbreak associated with Brilliant Blue G
Committee Members
Geoffrey G. Emerson, MD, PhD, Chair
Netan Choudhry, MD, FACS(C)
Harry W. Flynn Jr, MD
Sunir J. Garg, MD, FACS
Roger A. Goldberg, MD, MBA
Paul Hahn, MD, PhD
Stephen J. Kim, MD
Jennifer I. Lim, MD
Joel Pearlman, MD, PhD
Eric W. Schneider, MD
Michael A. Singer, MD
Homayoun Tabandeh, MD
Andre J. Witkin, MD
Robert W. Wong, MD
Charles C. Wykoff, MD, PhD
To report a potential adverse event
- Complete the ASRS Adverse Event Report Form
- Complete the FDA Medwatch Voluntary Reporting Form